Relevant bibliographies by topics / Nanoparticles, Breast Cancer, BOS

Academic literature on the topic 'Nanoparticles, Breast Cancer, BOS'

Author: Grafiati
Published: 9 March 2023
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Nanoparticles, Breast Cancer, BOS.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Nanoparticles, Breast Cancer, BOS"

1

Carney, Christine P., Nikhil Pandey, Anshika Kapur, Graeme F. Woodworth, Jeffrey A. Winkles, and Anthony J. Kim. "Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases." Drug Delivery and Translational Research 11, no. 6 (October 30, 2021): 2344–70. http://dx.doi.org/10.1007/s13346-021-01039-9.

Full text
Abstract:
AbstractBrain metastases (BMs) are the most common type of brain tumor, and the incidence among breast cancer (BC) patients has been steadily increasing over the past two decades. Indeed, ~ 30% of all patients with metastatic BC will develop BMs, and due to few effective treatments, many will succumb to the disease within a year. Historically, patients with BMs have been largely excluded from clinical trials investigating systemic therapies including immunotherapies (ITs) due to limited brain penetration of systemically administered drugs combined with previous assumptions that BMs are poorly immunogenic. It is now understood that the central nervous system (CNS) is an immunologically distinct site and there is increasing evidence that enhancing immune responses to BCBMs will improve patient outcomes and the efficacy of current treatment regimens. Progress in IT for BCBMs, however, has been slow due to several intrinsic limitations to drug delivery within the brain, substantial safety concerns, and few known targets for BCBM IT. Emerging studies demonstrate that nanomedicine may be a powerful approach to overcome such limitations, and has the potential to greatly improve IT strategies for BMs specifically. This review summarizes the evidence for IT as an effective strategy for BCBM treatment and focuses on the nanotherapeutic strategies currently being explored for BCBMs including targeting the blood–brain/tumor barrier (BBB/BTB), tumor cells, and tumor-supporting immune cells for concentrated drug release within BCBMs, as well as use of nanoparticles (NPs) for delivering immunomodulatory agents, for inducing immunogenic cell death, or for potentiating anti-tumor T cell responses. Graphical abstract
APA, Harvard, Vancouver, ISO, and other styles
2

Idhayadhulla, Akbar, Aseer Manilal, Anis Ahamed, Saud Alarifi, and Gurusamy Raman. "Potato Peels Mediated Synthesis of Cu(II)-nanoparticles from Tyrosinase Reacted with bis-(N-aminoethylethanolamine) (Tyr-Cu(II)-AEEA NPs) and Their Cytotoxicity against Michigan Cancer Foundation-7 Breast Cancer Cell Line." Molecules 26, no. 21 (November 3, 2021): 6665. http://dx.doi.org/10.3390/molecules26216665.

Full text
Abstract:
The synthesis of nanoparticles is most important in the context of cancer therapy, particularly copper nanoparticles, which are widely used. In this work, copper(II)-tyrosinase was isolated from potato peel powder. Copper nanoparticles (Tyr-Cu(II)-AEEA NPs) were synthesized via the reaction of tyrosinase with N-aminoethylethanolamine to produce Cu(II)-NPs and these were characterized by means of FT-IR, UV-Spectroscopy, XRD, SEM, TEM and a particle size analyzer. These Tyr-Cu(II)-AEEA NPs were tested as anticancer agents against MCF-7 breast cancer cells. Fluorescence microscopy and DNA fragmentation were also performed, which revealed the inhibiting potentials of Cu(II)-AEEA NPs and consequent cell death; Tyr-Cu(II)-AEEA NPs show potential cytotoxicity activity and this nano material could be contemplated as an anticancer medicament in future investigations.
APA, Harvard, Vancouver, ISO, and other styles
3

Padayachee, Jananee, and Moganavelli Singh. "Therapeutic applications of CRISPR/Cas9 in breast cancer and delivery potential of gold nanomaterials." Nanobiomedicine 7 (January 1, 2020): 184954352098319. http://dx.doi.org/10.1177/1849543520983196.

Full text
Abstract:
Globally, approximately 1 in 4 cancers in women are diagnosed as breast cancer (BC). Despite significant advances in the diagnosis and therapy BCs, many patients develop metastases or relapses. Hence, novel therapeutic strategies are required, that can selectively and efficiently kill malignant cells. Direct targeting of the genetic and epigenetic aberrations that occur in BC development is a promising strategy to overcome the limitations of current therapies, which target the tumour phenotype. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system, composed of only an easily modifiable single guide RNA (sgRNA) sequence bound to a Cas9 nuclease, has revolutionised genome editing due to its simplicity and efficiency compared to earlier systems. CRISPR/Cas9 and its associated catalytically inactivated dCas9 variants facilitate the knockout of overexpressed genes, correction of mutations in inactivated genes, and reprogramming of the epigenetic landscape to impair BC growth. To achieve efficient genome editing in vivo, a vector is required to deliver the components to target cells. Gold nanomaterials, including gold nanoparticles and nanoclusters, display many advantageous characteristics that have facilitated their widespread use in theranostics, as delivery vehicles, and imaging and photothermal agents. This review highlights the therapeutic applications of CRISPR/Cas9 in treating BCs, and briefly describes gold nanomaterials and their potential in CRISPR/Cas9 delivery.
APA, Harvard, Vancouver, ISO, and other styles
4

Odeyemi, Samuel Wale, and Anthony Jide Afolayan. "Characterization and Cytotoxicity Evaluation of Biologically Synthesized Silver Nanoparticles from Albuca setosa Aqueous Bulb Extract." International Journal of Nanoscience 18, no. 02 (January 30, 2019): 1850023. http://dx.doi.org/10.1142/s0219581x18500230.

Full text
Abstract:
Biologically synthesized nanoparticles are rapidly evolving because it is cost effective and eco-friendly, this also contributes to its preference over nanoparticles from other sources. In this study, silver nanoparticles were synthesized from Albuca setosa aqueous bulb (ASB) extracts and the biological activities evaluated. The silver nanoparticles were synthesized from ASB extracts using silver nitrate and characterized using UV–visible spectroscopy (UV–Vis), Fourier transform infrared spectroscopy (FTIR), scanning electron microscope (SEM), energy dispersive X-ray spectroscopy (EDX), X-ray diffraction (XRD) and transmission electron microscopy (TEM). The antioxidant activity was determined by evaluating the effect on 2,2-diphenyl-2-picrylhydrazyl (DPPH) scavenging activity, 2,2[Formula: see text]-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid diammonium salt (ABTS). The antibacterial potential was investigated on selected Gram positive and Gram negative bacteria while the cytotoxicity was evaluated on MDA-MB-231 breast cancer cells (ATCC HTB-26). Albuca setosa silver nanoparticles (AS-AgNPs) was formed within 60 min reaction time of UV–Vis absorption. The FTIR showed that acid anhydride, alkene, amine, aldehyde, ester, ketone and carbonyl groups contributed to the synthesis of the AS-AgNPs, while SEM and TEM showed stable irregular shaped monodispersed silver nanoparticles with average size of 7 nm. The XRD patterns revealed diffraction peaks at [Formula: see text] and 92.37∘ that was indexed to (1 1 0), (1 1 0), (1 0 0), (1 0 0) and (1 0 0) planes of face-centered cubic (fcc) crystalline structure respectively. The synthesized nanoparticles possess good antioxidant activity with IC50 of [Formula: see text] and [Formula: see text][Formula: see text][Formula: see text]g/ml for DPPH and ABTS, respectively, and inhibit the growth of Staphylococcus faecalis and Bacillus cereus with MIC of 25 and 15[Formula: see text][Formula: see text]g/ml respectively. AS-AgNPs also revealed higher cytotoxic efficacy against MDA-MB-231 breast cancer cells with IC50 of [Formula: see text][Formula: see text][Formula: see text]g/ml. AS-AgNPs showed acceptable size and shape of nanoparticles and could therefore be a potential source of antimicrobial and anticancer agents. It can be concluded that the synthesized AS-AgNPs is a good source of anticancer agent with broad spectrum of antibiotic activity.
APA, Harvard, Vancouver, ISO, and other styles
5

Bondon, Nicolas, Denis Durand, Kamel Hadj-Kaddour, Lamiaa M. A. Ali, Rabah Boukherroub, Nadir Bettache, Magali Gary-Bobo, et al. "Photosensitivity of Different Nanodiamond–PMO Nanoparticles in Two-Photon-Excited Photodynamic Therapy." Life 12, no. 12 (December 7, 2022): 2044. http://dx.doi.org/10.3390/life12122044.

Full text
Abstract:
Background: In addition to their great optical properties, nanodiamonds (NDs) have recently proved useful for two-photon-excited photodynamic therapy (TPE-PDT) applications. Indeed, they are able to produce reactive oxygen species (ROS) directly upon two-photon excitation but not with one-photon excitation; Methods: Fluorescent NDs (FNDs) with a 100 nm diameter and detonation NDs (DNDs) of 30 nm were compared. In order to use the gems for cancer-cell theranostics, they were encapsulated in a bis(triethoxysilyl)ethylene-based (ENE) periodic mesoporous organosilica (PMO) shell, and the surface of the formed nanoparticles (NPs) was modified by the direct grafting of polyethylene glycol (PEG) and amino groups using PEG-hexyltriethoxysilane and aminoundecyltriethoxysilane during the sol–gel process. The NPs’ phototoxicity and interaction with MDA-MB-231 breast cancer cells were evaluated afterwards; Results: Transmission electronic microscopy images showed the formation of core–shell NPs. Infrared spectra and zeta-potential measurements confirmed the grafting of PEG and NH2 groups. The encapsulation of the NDs allowed for the imaging of cancer cells with NDs and for the performance of TPE-PDT of MDA-MB-231 cancer cells with significant mortality. Conclusions: Multifunctional ND@PMO core–shell nanosystems were successfully prepared. The NPs demonstrated high biocompatibility and TPE-PDT efficiency in vitro in the cancer cell model. Such systems hold good potential for two-photon-excited PDT applications.
APA, Harvard, Vancouver, ISO, and other styles
6

Karakatsanis, A., K. Daskalakis, P. Stålberg, H. Olofsson, Y. Andersson, S. Eriksson, L. Bergkvist, and F. Wärnberg. "Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer." British Journal of Surgery 104, no. 12 (September 6, 2017): 1675–85. http://dx.doi.org/10.1002/bjs.10606.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kutwin, Marta, Ewa Sawosz, Sławomir Jaworski, Mateusz Wierzbicki, Barbara Strojny, Marta Grodzik, Malwina Ewa Sosnowska, Maciej Trzaskowski, and André Chwalibog. "Nanocomplexes of Graphene Oxide and Platinum Nanoparticles against Colorectal Cancer Colo205, HT-29, HTC-116, SW480, Liver Cancer HepG2, Human Breast Cancer MCF-7, and Adenocarcinoma LNCaP and Human Cervical Hela B Cell Lines." Materials 12, no. 6 (March 19, 2019): 909. http://dx.doi.org/10.3390/ma12060909.

Full text
Abstract:
Inefficient drug administration into cancer cells is related to the chemoresistance of cancer cells caused by genetic mutations including genes involved in drug transport, enzyme metabolism, and/or DNA damage repair. The objective of the present study was to evaluate the properties of platinum (NP-Pt), graphene oxide (GO), and the nanocomplex of GO functionalized with platinum nanoparticles (GO-NP-Pt) against several genetically, phenotypically, and metabolically different cancer cell lines: Colo205, HT-29, HTC-116, SW480, HepG2, MCF-7, LNCaP, and Hela B. The anticancer effects toward the cancer cell lines were evaluated by 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxyanilide salt (XTT) and bromodeoxyuridine (BrdU) assays and measurements of cell apoptosis and morphology deformations. The NP-Pt and GO could effectively be introduced to cancer cells, but more effective delivery was observed after GO-NP-Pt treatment. The delivery of the GO-NP-Pt nanocomplex significantly decreased the viability of Colo 205 and HepG2 cells, but did not increase the cytotoxicity of other investigated cancer cells. The nanocomplex GO-NP-Pt also significantly increased the apoptosis of Colo 205 and HepG2 cancer cells. The obtained results suggest that the nanocomplex GO-NP-Pt is a remarkable nanostructure that can improve the delivery of Pt nanoparticles into cancer cells and has potential anticancer applications.
APA, Harvard, Vancouver, ISO, and other styles
8

Riley, Rachel, Rachel O’Sullivan, Andrea Potocny, Joel Rosenthal, and Emily Day. "Evaluating Nanoshells and a Potent Biladiene Photosensitizer for Dual Photothermal and Photodynamic Therapy of Triple Negative Breast Cancer Cells." Nanomaterials 8, no. 9 (August 25, 2018): 658. http://dx.doi.org/10.3390/nano8090658.

Full text
Abstract:
Light-activated therapies are ideal for treating cancer because they are non-invasive and highly specific to the area of light application. Photothermal therapy (PTT) and photodynamic therapy (PDT) are two types of light-activated therapies that show great promise for treating solid tumors. In PTT, nanoparticles embedded within tumors emit heat in response to laser light that induces cancer cell death. In PDT, photosensitizers introduced to the diseased tissue transfer the absorbed light energy to nearby ground state molecular oxygen to produce singlet oxygen, which is a potent reactive oxygen species (ROS) that is toxic to cancer cells. Although PTT and PDT have been extensively evaluated as independent therapeutic strategies, they each face limitations that hinder their overall success. To overcome these limitations, we evaluated a dual PTT/PDT strategy for treatment of triple negative breast cancer (TNBC) cells mediated by a powerful combination of silica core/gold shell nanoshells (NSs) and palladium 10,10-dimethyl-5,15-bis(pentafluorophenyl)biladiene-based (Pd[DMBil1]-PEG750) photosensitizers (PSs), which enable PTT and PDT, respectively. We found that dual therapy works synergistically to induce more cell death than either therapy alone. Further, we determined that low doses of light can be applied in this approach to primarily induce apoptotic cell death, which is vastly preferred over necrotic cell death. Together, our results show that dual PTT/PDT using silica core/gold shell NSs and Pd[DMBil1]-PEG750 PSs is a comprehensive therapeutic strategy to non-invasively induce apoptotic cancer cell death.
APA, Harvard, Vancouver, ISO, and other styles
9

Chiu, Hock Ing, Che Nurul Azieyan Che Mood, Nur Nadhirah Mohamad Zain, Muggundha Raoov Ramachandran, Noorfatimah Yahaya, Nik Nur Syazni Nik Mohamed Kamal, Wai Hau Tung, Yoke Keong Yong, Chee Keong Lee, and Vuanghao Lim. "Biogenic Silver Nanoparticles of Clinacanthus nutans as Antioxidant with Antimicrobial and Cytotoxic Effects." Bioinorganic Chemistry and Applications 2021 (May 13, 2021): 1–11. http://dx.doi.org/10.1155/2021/9920890.

Full text
Abstract:
Silver nanoparticles (AgNPs) previously synthesised using leaf (AgNP-L) and stem (AgNP-S) extracts of Clinacanthus nutans (C. nutans) were tested to evaluate antimicrobial, antioxidant, and cytotoxicity activities. The AgNPs showed good inhibition against bacteria, but not fungi. The inhibition results showed the highest activity against Staphylococcus aureus (S. aureus) with 11.35 mm (AgNP-L) and 11.52 mm (AgNP-S), while the lowest inhibition was against Escherichia coli (E. coli) with 9.22 mm (AgNP-L) and 9.25 mm (AgNP-S) in the disc diffusion method. The same trend of results was noted in the well diffusion method. The IC50 of AgNP-L and AgNP-S in 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) assays was 417.05 μg/mL and 434.60 μg/mL, as well as 304.31 μg/mL and 326.83 μg/mL, respectively. Ferric reducing power (FRAP) assay showed that AgNP-L [872.389 μmol/L Fe(II)] and AgNP-S [612.770 μmol/L Fe(II)] exhibited significantly ( p < 0.05) greater antioxidant activities than leaf extract (CNL) [152.260 μmol/L Fe(II)] and stem extract (CNS) [110.445 μmol/L Fe(II)] of C. nutans. The AgNPs were also proven to possess cytotoxic effects on the breast (MCF-7), cervical (HeLa), and colon (HT-29) cancer cells in a dose-dependent manner. AgNP-S and AgNP-L showed significantly ( p < 0.05) higher cytotoxicity against MCF-7 (117.43 μg/mL) and HT-29 (78.47 μg/mL), respectively. In conclusion, the biosynthesised AgNPs from aqueous extract leaves and stem of C. nutans have demonstrated promising potential towards antioxidant, antimicrobial, and cytotoxicity activities.
APA, Harvard, Vancouver, ISO, and other styles
10

Koppiker, Chaitanyanand B., Santosh Dixit, Aijaz Ul Noor, Laleh Busheri, Gail Lebovic, Gautam Sharan, Upendra Dhar, and Smeeta Nare. "Breast Oncoplasty Surgery in Low- and Middle-Income Countries: Lessons From India." Journal of Global Oncology 4, Supplement 3 (October 2018): 22s. http://dx.doi.org/10.1200/jgo.18.10250.

Full text
Abstract:
Purpose Breast cancer is the most common cancer in India, affecting all socio-economic strata. Despite its growing global acceptance, Breast Oncoplasty Surgery (BOS) remains nascent in India, necessitating local context-specific innovative delivery models for clinicians and the general public. Here, we present experiences from Orchids Breast Health Clinic (OBHC; Pune, India) with the implementation of BOS clinical services, training, and research and community outreach. Methods OBHC, a dedicated breast unit, has established the first dedicated BOS clinic in India, conducted hands-on training workshops for trainee surgeons, developed an MCh degree program in breast oncoplasty with the University of East Anglia (Norwich, United Kingdom), undertaken BOS research in Indian patients, and created outreach programs to popularize BOS. Results A cost-effective one surgeon–dual role concept wherein the same surgeon performs onco- and plastic surgery and one-stage implant-based breast reconstruction has been adopted. Since 2013, BOS cases included BCS (n = 440), breast reconstruction (n = 210), and therapeutic mammoplasty (n = 135). The unavailability of acellular dermal matrices has prompted the innovation of a surgical technique, termed Advanced Autologous Dermal Sling, which uses vascularized local tissue as implant cover. Significant improvement in postsurgery outcomes and protection against radiation complications has been observed. BOS hospitalization costs have been reduced by 50% thereby, which has led to high rates of acceptance (80%) of BOS in patients at OBHC. Young breast surgeons from across India and South Asian Association for Regional Cooperation countries have enrolled in the MCh degree program, which involves an embedded curriculum with online didactic modules and hands-on training workshops in Pune, India. Longitudinal follow-up after 1, 3, and 5 years postsurgery in the study cohorts is undertaken for post-BOS outcomes using clinical assessment (Bakers scale) and patient-reported outcomes measures (BREAST-Q questionnaire). Multiple research projects are undergoing peer-review before publication. To increase awareness of BOS among Indian women, community awareness campaigns with the theme of Losing Is Not an Option are underway via public talks, symposia, marathon, and op-eds in electronic and print media. Conclusion The OBHC model of Affordable Excellence in BOS, developed in the Indian context, can be extrapolated to benefit patients with breast cancer from other low- and middle-income countries. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc . No COIs from the authors.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Nanoparticles, Breast Cancer, BOS"

1

PANDOLFI, LAURA. "Investigating the effects of drug-loaded nanoparticles on the cellular behavior of proliferative diseases." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2016. http://hdl.handle.net/10281/101974.

Full text
Abstract:
A common feature of nanoparticles (NPs) is their large surface area to volume ratio that makes them an attractive tools for the development of drug delivery systems, improving several properties of ‘‘free’’ drugs: solubility, pharmacokinetic profile and biodistribution. During my PhD, I studied different nanovehicles loaded with “free” hydrophobic drugs against three “over-proliferative” diseases to evaluate the efficacy and safety of nanodrugs. In the first year, I focused the anti-proliferative effect of ASC-J9, a promise in the treatment of prostate cancer. ASC-J9 is a very hydrophobic molecule, which limits drug administration. ASC-J9 was loaded on PLGA NPs, in order to improve the solubility of the molecule and applied to an estrogen-dependent breast cancer. My results showed a cellular growth inhibition associated with a specific G2/M cell cycle block, which led to apoptosis. In the second year, I worked in collaboration with group of IRCCS San Matteo (PV). In a previous work (2014), Cova et al evaluated the effectiveness of gold NPs functionalized with anti-CD44 monoclonal antibody loaded with everolimus (GNP-HCe), prepared by our laboratory, in inhibiting mesenchymal cells (MCs), the primarily responsible for the bronchiolitis obliterans syndrome (BOS). Considering that BOS is due to an alteration of inflammatory process the aim is determined the effect of GNP-HCe on macrophages, neutrophils and lymphocytes with in vitro assays assessing cytokine secretion, cell apoptosis and ROS production. Next, we administered GNP-HCe by aerosolization in normal mice evaluating the localization and toxicity on lungs and peripheral organs. GNP-HCe were able to reduce ROS and not to enhance the activity of three major components of immune response. The in vivo experiments confirmed that inhaled NPs did not raise the inflammatory response, because the bronchoalveolar lavage of mice did not show significant increase of IL-8 cytokine. This study discloses the possibility to plan a new pharmacological treatment for patients affected by pulmonary fibroproliferative disorders directly targeting MCs without altering the immune response. During the last year, I focused on triple negative breast cancer (TNBC) representing only the 15% of breast cancers, but the most aggressive phenotype. TNBCs lack three specific molecular markers (ER, PR and HER-2), which makes the current chemotherapeutic approaches mostly ineffective. TNBC cells show strong drug resistance due to the overexpression of P-glycoprotein (Pgp), MDR-associated proteins (MRP1), and breast cancer resistance protein (BCRP) that actively efflux the drug outside the cells conferring resistance to treatment. Curcumin possesses a wide range of pharmacological activities; one is the capacity to modulate the MDR activity in different type of cancer cells, affecting the expression and the functionality of MDR proteins. There are no data in literature on TNBC cells, so, we aim to evaluate modulation of Pgp, MRP1 and BCRP expression and their functionality in two different TNBC cell lines (MDA-MB-468 and MDA-MB-231) after treatment with curcumin. One of the problems is the lipophilic nature of this molecule; thus, to improve the drug solubility, we encapsulated curcumin inside H-ferritin nanocages (HFn). We have demonstrated that HFn recognize transferrin receptor 1 (TfR1), overexpressed by TNBC cells, with high binding capacity. The HFn-TfR1 interaction mediates the internalization of HFn, which disassembles into subunits inside the cytoplasm, allowing the intracellular release of drugs. Work is in progress to assess the effect of HFn-curcumin on TNBCs
APA, Harvard, Vancouver, ISO, and other styles
2

He, Felicia Jane. "Targeting Metastatic Breast Cancer Using Dual-Ligand Nanoparticles." Case Western Reserve University School of Graduate Studies / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=case1499699087340348.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

COLOMBO, MIRIAM. "Synthesis and biofunctionalization of nanoparticles for breast cancer diagnosis and treatment." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2012. http://hdl.handle.net/10281/28928.

Full text
Abstract:
The early identification of the insurgence of a malignant cancer and the selective targeting of the tumor with specific drugs are still an open frontier for cancer diagnosis and treatment. The ultimate goal is to improve the therapy efficiency and to reduce the side effects usually encountered with conventional chemotherapy. Worldwide, mammary carcinoma represents the second most recurrent type of malignant tumor in adult women and the fifth cause of death among cancer types. In the context of this thesis, I have designed and developed multifunctional hybrid nanoparticles consisting of an inorganic iron oxide core, useful as source of signal for magnetic resonance imaging (MRI), and an organic shell, including bioactive ligands for the pharmacological effect combined with specific cell targeting, and a molecular dye as fluorescence signal emitter. The nanoparticle characteristics were optimized in terms of size, morphology, surface charge, stability, fluorescence emission and capability to enhance the MRI contrast. In addition, specific biomolecular ligands based on anti-HER-2 monoclonal antibody have been developed and novel strategies for their conjugation to nanoparticles were explored. The resulting hybrid nanocomplexes were tested both in vitro and in vivo to evaluate their toxicity, endocytosis, degradation pathways, and the efficient recognition of cell-surface biomarkers. Next, these nanoparticles proved to be highly effective in selectively targeting breast cancer cells in transplanted mice bearing HER-2-positive tumors. A multifaceted bioanalytical approach, combining fluorescence, magnetic relaxivity, transmission electron microscopy, and histological experiments in vivo and ex vivo, has demonstrated that these nanoprobes prevalently accumulated at the tumor by an active targeting route. The nanoparticles were endocytosed by the tumor cells following a lysosomal pathway of degradation, while did not result in permanent damage of healthy tissues. The principal outcome of this work was the development of a versatile and reliable biotechnological platform based on finely structured, multifunctional nanosized probes useful for the interrogation of biological systems.
APA, Harvard, Vancouver, ISO, and other styles
4

Sebak, Safaa. "Novel nanoparticles for breast cancer targeted delivery: preparation and in vitro characterization." Thesis, McGill University, 2009. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=86928.

Full text
Abstract:
Breast cancer is the second most common type of cancer after lung cancer and the fifth most common cause of cancer death. It is by far the most widespread cancer amongst women, with an incidence rate of more than twice that of colorectal cancer and cervical cancer and about three times that of lung cancer. In this thesis, for the first time, a novel nanoparticle for effective drug delivery using the antibody trastuzumab and genipin crosslinking agent was designed and evaluated for its use in breast cancer. In vitro studies were also conducted to compare different crosslinkers in the preparation method of the drug loaded nanoparticles. In addition the efficacy of noscapine drug loaded nanoparticles were evaluated in breast cancer cell lines. Results showed that novel nanoparticles containing targeting antibody trastuzumab can be an alternate method for breast cancer treatment and other biomedical applications. This work highlights the potential of novel antibody targeting nanoparticles crosslinked with genipin or glutaraldehyde as a drug delivery system for breast cancer therapy as they can effectively deliver drugs such as noscapine. Further in-vivo studies however are required to evaluate the full potentials.
Suivant le cancer des poumons, le cancer du sein est le deuxième type de cancer le plus répandu et commun à travers le monde. C'est la cinquième cause de décès du à un cancer. Certes, il est le cancer le plus commun parmi les femmes, ayant un double taux d'incidence à ceux du cancer du colon et cancer du col de l'utérus, et triple à celui des poumons. Dans cette dissertation, une drogue carrière qui combine les anticorps trastuzumab et la drogue noscapine, a été conçue et évaluée pour être utilisée dans le traitement du cancer du sein. Des études « in vitro » ont étés conduites pour comparer différents crosslinkers dans la méthode de préparation des nanoparticules chargées de cette drogue. De plus, l'efficacité de nanoparticules chargées de drogues a été évaluée au niveau des cellules du cancer de sein. L'objectif de cette étude est le développement d'une procédure coacervation pour la préparation et la caractérisation in vitro des nanoparticules HSA sous un aspect d'une taille contrôlée, en combinaison d'une distribution mono dispersée. Leur propriétés sont donc étudiés pour la délivrance optimale, prudente et efficace de drogues anti-cancer. Les résultats prouvent que les nanoparticules chargées de noscapine qui contiennent l'anticorps trastuzumab peuvent être une méthode alternative pour le traitement du cancer du sein ainsi que d'autres applications biomédicales. Des études "in-vivo" plus profondes sont recommanés pour évaluer leur potentiel maximum. Ce travail mets en valeur le potentiel des trastuzumab-modifié nanoparticules charges de noscapine reliés avec du genipin ou du glutaraldehyde comme un system de drogue conçu pour la thérapie du cancer du sein. fr
APA, Harvard, Vancouver, ISO, and other styles
5

Johnson, Laura. "Magnetic nanoparticles for sentinel lymph node imaging and biopsy in breast cancer." Thesis, King's College London (University of London), 2012. https://kclpure.kcl.ac.uk/portal/en/theses/magnetic-nanoparticles-for-sentinel-lymph-node-imaging-and-biopsy-in-breast-cancer(978692de-a495-4df1-ac0f-303227bed0dd).html.

Full text
Abstract:
Background Axillary nodal status is the single most important prognostic factor in breast cancer diagnosis. If cancerous cells are present, the sentinel lymph node (SLN) is the axillary lymph node that is most likely to contain metastatic disease. In early stage breast cancer, the SLN is localised (then surgically removed for pathological analysis) using a radioisotope and/or a blue dye injected into the breast Super-paramagnetic iron oxide (SPIO) nanoparticles are novel agents that, when injected, could potentially both localise and characterise the SLN using MRI such that surgical SLN biopsy is no longer required. Aims To evaluate axillary SLN localisation after SPIO injection with, pre-operatively, axillary MRI and, intra-operatively, with a hand held magnetometer and to characterise SLN SPIO uptake using ex-vivo MRI. Methods From November 2009 - March 2011, 51 patients with early stage breast cancer underwent SLN biopsy following a subcutaneous injection of SPIO in addition to the standard injection of radioisotope (Tc99M) and blue dye. SPIO injection technique was refined during the trial with an initial dose of 2mls and then 4mls in 8 and then 43 women respectively. Pre-operative axillary in vivo MRI (1.5T) was carried out on 14 women and ex vivo high resolution MRI (9.4T) on 36 nodes. During surgery, an SLN was defined as either "hot", "blue", "palpable" or "SPIO detected". Axillary clearance was carried out for SLN-positive disease. Results In total, 11 of the 51 patients had positive SLNs. On pre-operative axillary MRI, SPIO uptake was noted in at least one node in all 14 patients. A total of 35 nodes were identified. Uptake of SPIO in the SLN was seen at a minimum of 12mins post injection. Involved SLNs were not differentiated from normal SLNs following morphological characterisation or based on loss of T2 signal within the individual SLN. At SLN biopsy, 134 hot, blue, palpable or SPIO-containing nodes were identified in 51 patients. The magnometer identified 92 SPIO-containing nodes in 51 (84%) patients. One node in one patient was not identified using the combined technique but was found to contain SPIO. Of the 16 hot, blue or palpable involved nodes in 11 patients, 9 contained SPIO. In summary, the SPIO SLN localisation rate and FNR in patients was 84% and 16% respectively. Ex vivo SLN MRI demonstrated SPIO uptake in all 35 SLNs preferential to the sinuses and sub-capsular spaces. Of the 3 involved nodes, areas of metastasis did not take up SPIO, whereas in normal areas of the node, SPIO was positively identified. Conclusion In our study, subcutaneous SPIO, a novel SLN-localising agent, was taken up by axillary nodes and identified on pre-operative axillary MRI. Node positive SLNs were identified on ex vivo MRI, but SPIO did not demonstrate sufficient accuracy at SLN localisation for routine clinical use.
APA, Harvard, Vancouver, ISO, and other styles
6

RAINONE, PAOLO. "99MTC-RADIOLABELED NANOPARTICLES FOR TARGETED DETECTION AND TREATMENT OF HER2-POSITIVE BREAST CANCER." Doctoral thesis, Università degli Studi di Milano, 2020. http://hdl.handle.net/2434/701981.

Full text
Abstract:
Introduction: The HER2 receptor overexpression is normally associated to aggressive and infiltrating breast cancer (BC) phenotype with propensity to spread into metastases. Nowadays, the detection of HER2 in primary tumor lesions and in their metastases is based on invasive methods as well therapy clinical outcomes are not satisfactory yet. Recent advances in nanotechnology have led to the development of nanoparticles able to host various functionalities for specific targeting and to be loaded with therapeutic molecules, making possible the simultaneous diagnosis and treatment of human cancers (theranostic). In the present Thesis study, was evaluated the potential use of targeted silica nanoparticles (SiNPs) as theranostic agent for HER2+ breast cancer. Methods: SiNPs were engineered with anti-HER2 monoclonal antibody Trastuzumab, in the form of half-chain (Hc-TZ), and radiolabeled employing 99mTc for in vivo SPECT imaging detection of HER2+ BC lesions. Subsequently, SiNPs were loaded with doxorubicin (DOX) for treatment evaluation. Experimental design was divided in three main tasks. First, we evaluated the contribution offered by active targeting (Hc-TZ) to the selective distribution of SiNPs in solid HER2 positive BC lesions. To this aim, both Hc-TZ conjugated (SiNP-TZ) and non-conjugated (SiNP) nanosilica shells were radiolabeled with 99mTc-Tricarbonyl complex, through nitrilotriacetic acid (NTA) linker procedure, and their distribution kinetics evaluated in vitro and ex vivo in ad hoc cancer models. Nanoparticles were simultaneous filled with a fluorescent dye and their uptake were also assessed by FACS analysis and fluorescence microscopy. In the second experimental step, nanoparticles were also engineered with several amount of Hc-TZ (SiNPs to Hc-TZ ratio, 1:2 and 1:8 respectively), and were 99mTc-labeled at histidine residues of the antibody chain for ex vivo/in vivo biodistribution evaluation. Finally, SiNP-TZ were loaded with DOX and in vitro/in vivo DOX distribution in HER2 positive models was evaluated using confocal microscopy and Optical Imaging, in comparison to liposomal doxorubicin (Caelyx). The treatment efficacy of DOX-SiNP-TZ (1:8 Hc-TZ) versus Caelyx was evaluated in vivo for six weeks of treatment, also using PET molecular imaging ([18F]FDG) approach. Results: In vitro assays showed a higher fluorescence signal (FICT) in SK-BR-3 compared to MDA-MB-468 cells, exclusively for targeted SiNP-NTA-TZ/SiNP-TZ with an increase over time. Ex vivo biodistribution of 99mTc-labelled nanoparticles via NTA, at 4 h post-injection of SiNP-NTA-TZ and/or non-targeted (SiNP-NTA), exhibited values of 3.53 and 1.69 in tumor (tumor to muscle ratio) respectively, with a rapid reduction over time for targeted nanoparticles. These results indicated the presence of an antibody-receptor mediated tumor uptake of SiNP-NTA-TZ, with a faster washout of nanoparticles radiolabeled shell. In the second set of experiments, performed with 99mTc-SiNP-TZ labelled on TZ half chain, uptake was confirmed at 4 h p.i. for SiNP-TZ (1:8 Hc-TZ) with similar results to SiNP-TZ (1:2 Hc-TZ). Instead, was showed a progressive retention of radioactivity until 24 h p.i., confirming the presence of radiolabeled Hc-TZ to the tumor also at latter times, with improved results for SiNP-TZ (1:8 Hc-TZ), also in terms of radiochemical yield. Doxorubicin loaded SiNP-TZ (1:8 Hc-TZ) showed in vivo similar delivery results in comparison to Caelyx at 6 h p.i., meanwhile at the end of treatment tumor volume reduction resulted significant improved by targeted nanoparticles administration. Conclusion: Results of this Thesis study, demonstrated a promising specificity and treatment efficacy of the silica nanoparticles-based system SiNP-TZ, encouraging its potential use as theranostic agent for HER2+ breast cancer lesions.
APA, Harvard, Vancouver, ISO, and other styles
7

Allard, Garvin Richard Johan. "Synthesis and characterization of zinc-doped magnetic nanoparticles for diagnostic studies." University of the Western Cape, 2015. http://hdl.handle.net/11394/4815.

Full text
Abstract:
Magister Scientiae - MSc
In the present study we report the synthesis and characterization of iron oxide magnetic nanoparticles doped with zinc in an attempt to enhance the magnetic properties. The nanoparticles were prepared via the co-precipitation route and capped with 3-phosphonopropionic acid (3-PPA). The amount of zinc dopant was varied to yield nanoparticles with the general formula ZnxFe3-xO4 (x=0, 0.1, 0.2, 0.3, 0.4). Characterization was carried out using high resolution transmission electron microscopy (HRTEM), X-ray diffraction spectroscopy (XRD), energy-dispersive X-ray spectroscopy (EDS), Fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA) and superconducting quantum interference device (SQUID) analysis. Results from HRTEM, XRD and SQUID confirm that doping took place and x=0.2 was found to be the doping limit for these nanoparticles with a maximum size of 10.73 nm and saturation magnetization of 73.37 emu/g. The EDS further confirmed successful doping with zinc, while FTIR and TGA confirmed successful capping with 3-PPA. Despite agglomeration at all doping levels, these nanoparticles show great potential for application in breast cancer diagnostic studies.
APA, Harvard, Vancouver, ISO, and other styles
8

BELLINI, MICHELA. "Development of apoferritin nanoparticles for chemotherapeutic delivery and drug resistance overcoming in breast cancer models." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2017. http://hdl.handle.net/10281/158296.

Full text
Abstract:
Cancer is a leading cause of disease worldwide and breast cancer, which exists in four major molecular subtypes, is the second most common cause of cancer mortality. Although there are many therapeutic options, chemotherapy is still subject to failures, due to (1) the low selectivity of drugs, which requires high doses with side effects and the risk of recurrence and (2) the development of resistance by different mechanisms that cells put in place to defend themselves from the action of drugs. In my PhD project I exploited the unique features of a nanoparticle based on recombinant heavy-chain ferritin cages (HFn) for the targeted delivery of various active molecules to improve the treatment efficacy in breast cancer. My work is divided into three main subprojects, all sharing the use of HFn. Initially, I exploited HFn nanocages for the encapsulation of a chemotherapeutic drug, doxorubicin (DOX). HFn-DOX acts as a “Trojan Horse”: nanoparticles are internalized in cancer cells faster and more efficiently compared to free DOX, then promptly translocated into the nucleus with a self-triggered mechanism, thus promoting a fast and massive delivery of the drug inside the nuclear compartment, strongly affecting viability and circumventing MDR mechanisms. Then, I tested HFn-DOX on an aggressive breast cancer model, in vitro and in vivo, under a Low Dose Nanometronomic regimen (LDNM). Metronomic HFn-DOX strongly improved the antitumor potential of DOX chemotherapy arresting the tumor progression. Such effect is attributable to multiple nanodrug actions, including inhibition of tumor angiogenesis and avoidance of chemoresistance. Moreover, metronomic HFn-DOX drastically reduced cardiotoxicity. In the second project, curcumin was encapsulated in HFn (CFn) and used to treat triple negative breast cancer (TNBC) cell lines. Curcumin is a natural anti tumor compound, but is rapidly degraded and scantily bioavailable. CFn had instead good stability and solubility and was able to enhance the sensitization of TNBC cells to DOX treatment. Finally, HFn was used as a vehicle to transport anti-microRNAs, since miR21 plays a role in the development of resistance against Trastuzumab (TZ), the treatment of choice for HER2 positive breast cancer. The major limiting factor in gene therapy is the ability to specifically deliver nucleotide sequences: however, anti-miR21 cross-linked to HFn, was released into the cytoplasm. Based on our results, ferritin is an effective system for the delivery of anti-tumor molecules, promoting their chemotherapic action and/or overcoming the problem of resistance that limits the effectiveness of many therapies.
Cancer is a leading cause of disease worldwide and breast cancer, which exists in four major molecular subtypes, is the second most common cause of cancer mortality. Although there are many therapeutic options, chemotherapy is still subject to failures, due to (1) the low selectivity of drugs, which requires high doses with side effects and the risk of recurrence and (2) the development of resistance by different mechanisms that cells put in place to defend themselves from the action of drugs. In my PhD project I exploited the unique features of a nanoparticle based on recombinant heavy-chain ferritin cages (HFn) for the targeted delivery of various active molecules to improve the treatment efficacy in breast cancer. My work is divided into three main subprojects, all sharing the use of HFn. Initially, I exploited HFn nanocages for the encapsulation of a chemotherapeutic drug, doxorubicin (DOX). HFn-DOX acts as a “Trojan Horse”: nanoparticles are internalized in cancer cells faster and more efficiently compared to free DOX, then promptly translocated into the nucleus with a self-triggered mechanism, thus promoting a fast and massive delivery of the drug inside the nuclear compartment, strongly affecting viability and circumventing MDR mechanisms. Then, I tested HFn-DOX on an aggressive breast cancer model, in vitro and in vivo, under a Low Dose Nanometronomic regimen (LDNM). Metronomic HFn-DOX strongly improved the antitumor potential of DOX chemotherapy arresting the tumor progression. Such effect is attributable to multiple nanodrug actions, including inhibition of tumor angiogenesis and avoidance of chemoresistance. Moreover, metronomic HFn-DOX drastically reduced cardiotoxicity. In the second project, curcumin was encapsulated in HFn (CFn) and used to treat triple negative breast cancer (TNBC) cell lines. Curcumin is a natural anti tumor compound, but is rapidly degraded and scantily bioavailable. CFn had instead good stability and solubility and was able to enhance the sensitization of TNBC cells to DOX treatment. Finally, HFn was used as a vehicle to transport anti-microRNAs, since miR21 plays a role in the development of resistance against Trastuzumab (TZ), the treatment of choice for HER2 positive breast cancer. The major limiting factor in gene therapy is the ability to specifically deliver nucleotide sequences: however, anti-miR21 cross-linked to HFn, was released into the cytoplasm. Based on our results, ferritin is an effective system for the delivery of anti-tumor molecules, promoting their chemotherapic action and/or overcoming the problem of resistance that limits the effectiveness of many therapies.
APA, Harvard, Vancouver, ISO, and other styles
9

Weng-Jiang, Xian. "Aqueous in-flow synthesis of T1 enhancing iron oxide nanoparticles for breast cancer theranostics." Thesis, University College London (University of London), 2017. http://discovery.ucl.ac.uk/10040653/.

Full text
Abstract:
Superparamagnetic iron oxide nanoparticles (SPIONs) have gained signif- icant interest over the past decades because of their wide range of appli- cations. In biomedicine, SPIONs had been used extensively in the past as MRI contrast agents but they are currently being investigated for hyperther- mia therapies, magnetic manipulation and as part of diagnostic devices. The main aim of this study is to develop a method to synthesise positive MRI enhancing iron oxide nanoparticles (T1) and use these as the diagnos- tic component to produce a theranostic (therapeutic and diagnostic) agent. An aqueous flow-based synthesis method was assembled and tested producing 25nm iron oxide nanoparticles with T1 enhancement, CMDxUS- PIONs. The devised synthetic method enabled the fabrication of the desired nanoparticles without the use of organic solvents and at higher outputs than previously reported with flow-based methods, with 12 clinical doses being produced per hour using a lab-scale system. Surface functionalisation of CMDxUSPIONs with aptamers for active targeting was accomplished using a recently discovered anti-annexin 2A aptamer (ACE4). Particle uptake results show that ACE4-CMDxUSPIONs presented at least a two-fold increase in cell uptake when compared to un- modified CMDxUSPIONs. Further modifications of CMDxUSPIONs included drug-loading with cisplatin. Cisplatin loaded CMDxUSPIONs (CPt-CMDxUSPIONs) were achieved following pre-optimisation using a Design of Experiments ap- proach. The drug-loaded CPt-CMDxUSPIONs containing 0.64mg of CPt/mg of iron were able to retain both the activity of free cisplatin (in vitro) and the imaging capabilities of CMDxUSPIONs. In vivo experiments using a 4T1 mammary carcinoma cell line in Balb/C mice showed that CPt-CMDxUSPIONs were trackable in a 1T preclinical MRI and therapeutically, CPt-CMDxUSPIONs reduced tumour size and minimised cisplatin’s nephro- toxicity. Moreover, preclinical MRI scans show that it is possible to use CMDxUSPIONs as reporters for nanoparticle uptake detected by a T1-T2 signal switch in MRI. Iron oxide based theranostic systems reported in this thesis could play an important role in future cancer treatments by enabling a personalised therapy approach and modifying current chemotherapeutic drug biodistribu- tion as a carrier. The facile synthesis together with the addition of therapeu- tic agents to iron oxide nanoparticles demonstrates that the production of an experimental theranostic is possible.
APA, Harvard, Vancouver, ISO, and other styles
10

Kennell, Carly M. "Synthesis and Characterization of Hybrid Co-Delivery Nanoparticles for Triple Negative Breast Cancer Treatment." University of Cincinnati / OhioLINK, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1470741290.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Nanoparticles, Breast Cancer, BOS"

1

Riaz, Ramish, and Abdullah Ahmad. "Nanoparticles: Emerging Diagnostic and Therapeutic Agents for Breast Cancer Treatment." In Breast Cancer: From Bench to Personalized Medicine, 453–76. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-0197-3_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sun, Bing Feng, and Si Shen Feng. "Trastuzumab Decorated Nanoparticles for Targeted Chemotherapy of Breast Cancer." In Advances in Science and Technology, 160–65. Stafa: Trans Tech Publications Ltd., 2008. http://dx.doi.org/10.4028/3-908158-14-1.160.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Silva, J. G., J. Maldonado, J. S. Tapia, N. E. Herrera, S. M. Polo, S. G. Martínez, and C. A. González. "Selective Targeting of Breast Cancer Cells MCF-7 by Ferromagnetic Nanoparticles." In V Latin American Congress on Biomedical Engineering CLAIB 2011 May 16-21, 2011, Habana, Cuba, 983–86. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-21198-0_250.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rammelkamp, Derek, Weiyi Li, and Yizhi Meng. "Intracellular Delivery of Fluorescently Labeled Polysaccharide Nanoparticles to Cultured Breast Cancer Cells." In Methods in Molecular Biology, 289–302. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3444-7_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

De Silva, Leanne, Bey-Hing Goh, Learn-Han Lee, and Lay-Hong Chuah. "Curcumin-Loaded Nanoparticles and Their Potential as Anticancer Agents in Breast Cancer." In Natural Bio-active Compounds, 147–78. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-7205-6_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Harini, Lakshminarasimhan, Karthikeyan Bose, T. Mohan Viswanathan, Nachimuthu Senthil Kumar, Krishnan Sundar, and Thandavarayan Kathiresan. "Mesoporous Silica Nanoparticles Are Nanocarrier for Drug Loading and Induces Cell Death in Breast Cancer." In Environmental Chemistry for a Sustainable World, 225–45. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-77795-1_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ahmad, Rozaina, Noor Haida Mohd Kaus, and Shahrul Hamid. "Synthesis and Characterization of PLGA-PEG Thymoquinone Nanoparticles and Its Cytotoxicity Effects in Tamoxifen-Resistant Breast Cancer Cells." In Advances in Experimental Medicine and Biology, 65–82. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/5584_2018_302.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Finas, Dominique, Kristin Baumann, Katja Heinrich, Britta Ruhland, Lotta Sydow, Ksenija Gräfe, Timo Sattel, Kerstin Lüdtke-Buzug, and Thorsten Buzug. "Distribution of Superparamagnetic Nanoparticles in Lymphatic Tissue for Sentinel Lymph Node Detection in Breast Cancer by Magnetic Particle Imaging." In Springer Proceedings in Physics, 187–91. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-24133-8_30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sowmiya, R., Tanakorn Osotchan, and Dakrong Pissuwan. "The Impact of Gold Nanoparticles with Low Energy Irradiation Treatment on Temperature Induction and Cell Viability of Breast Cancer Cell." In Proceedings of the International Conference on Nanomedicine (ICON-2019), 86–93. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-25135-2_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Khosroshahi, M. E., M. Tajabadi, Sh Bonakdar, and V. Asgari. "Synthesis and Characterization of SPION Functionalized third Generation dendrimers Conjugated by Gold Nanoparticles and Folic acid for Targeted Breast Cancer Laser Hyperthermia: An Invitro-assay." In IFMBE Proceedings, 823–26. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-19387-8_201.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Nanoparticles, Breast Cancer, BOS"

1

Natarajan, Arutselvan, Senthil K. Venugopal, Sally J. DeNardo, and Mark A. Zern. "Breast cancer targeting novel microRNA-nanoparticles for imaging." In SPIE BiOS: Biomedical Optics, edited by Fred S. Azar and Xavier Intes. SPIE, 2009. http://dx.doi.org/10.1117/12.812186.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Xu, Guoqiang, Qiaoya Lin, Lichao Lian, Yuan Qian, Lisen Lu, and Zhihong Zhang. "CT/FMT dual-model imaging of breast cancer based on peptide-lipid nanoparticles." In SPIE BiOS, edited by Wei R. Chen. SPIE, 2016. http://dx.doi.org/10.1117/12.2214270.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Vivero-Escoto, Juan L., Laura Moore Jeffords, Didier Dréau, Merlis Alvarez-Berrios, and Pinku Mukherjee. "Mucin1 antibody-conjugated dye-doped mesoporous silica nanoparticles for breast cancer detection in vivo." In SPIE BiOS, edited by Marek Osiński, Wolfgang J. Parak, and Xing-Jie Liang. SPIE, 2017. http://dx.doi.org/10.1117/12.2252369.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tate, Jennifer A., Mark D. Savellano, and P. Jack Hoopes. "Biodistribution and imaging of fluorescently-tagged iron oxide nanoparticles in a breast cancer mouse model." In SPIE BiOS, edited by Thomas P. Ryan. SPIE, 2013. http://dx.doi.org/10.1117/12.2007607.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tate, Jennifer A., Warren Kett, Christian NDong, Karl E. Griswold, and P. Jack Hoopes. "Biodistribution of antibody-targeted and non-targeted iron oxide nanoparticles in a breast cancer mouse model." In SPIE BiOS, edited by Thomas P. Ryan. SPIE, 2013. http://dx.doi.org/10.1117/12.2008814.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Xie, X., W. Deng, M. Yang, J. Tang, X. Wang, W. Wei, Z. Xie, et al. "“VISA” Nanoparticles to Breast Cancer." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-5159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

de Souza Braga, Marina, Gabriela Correa Carvalho, Kamal Dua, Gaurav Gupta, Adriano Oliveira, Natalia Cerize, and Terezinha J. A. Pinto. "Idarubicin Loaded Nanoparticles for Breast Cancer." In The 3rd World Congress on Recent Advances in Nanotechnology. Avestia Publishing, 2018. http://dx.doi.org/10.11159/nddte18.119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ghiciuc, Cristina Mihaela, Loredana Beatrice Ungureanu, Raluca Stefania Stanescu, and Raoul Vasile Lupusoru. "Nanoparticles in the Therapy of Breast Cancer." In 2019 E-Health and Bioengineering Conference (EHB). IEEE, 2019. http://dx.doi.org/10.1109/ehb47216.2019.8970021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Urdaneta, Maryory, and Parveen Wahid. "Enhancing hyperthermia treatment for breast cancer using nanoparticles." In 2013 IEEE International Symposium on Antennas and Propagation & USNC/URSI National Radio Science Meeting. IEEE, 2013. http://dx.doi.org/10.1109/aps.2013.6711680.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ronchi, Silvia, Miriam Colombo, Paolo Verderio, Serena Mazzucchelli, Fabio Corsi, Clara De Palma, Raffaele Allevi, Emilio Clementi, Davide Prosperi, and Elisabetta Borsella. "Magnetofluorescent nanoparticles for bimodal detection of breast cancer cells." In BONSAI PROJECT SYMPOSIUM: BREAKTHROUGHS IN NANOPARTICLES FOR BIO-IMAGING. AIP, 2010. http://dx.doi.org/10.1063/1.3505055.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Nanoparticles, Breast Cancer, BOS"

1

Yang, Shanmin. Targeting of Breast Cancer with Triptolide Nanoparticles. Fort Belvoir, VA: Defense Technical Information Center, August 2005. http://dx.doi.org/10.21236/ada441278.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Vishwanatha, Jamboor. Breast Cancer Therapy With Annexin 11 Nanoparticles. Fort Belvoir, VA: Defense Technical Information Center, May 2006. http://dx.doi.org/10.21236/ada457045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Suh, Junghae. Targeted Virus Nanoparticles for Localized Chemotherapy of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2010. http://dx.doi.org/10.21236/ada538233.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Panchapakesan, Balaji. Applications of Nanoparticles/Nanowires and Carbon Nanotubes for Breast Cancer Research. Fort Belvoir, VA: Defense Technical Information Center, September 2004. http://dx.doi.org/10.21236/ada431597.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jo, Seongbong, Han-Joung Cho, Jung-Eun Base, and Vivek K. Garripelli. Hypoxia-sensitive, Multifunctional Nanoparticles for Targeted Drug Delivery to Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2012. http://dx.doi.org/10.21236/ada567915.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Adams, Gregory P. Radiopaque, Tumor-Targeted Nanoparticles for Improved Mammographic Detection of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2007. http://dx.doi.org/10.21236/ada474676.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Halas, Naomi J. Seamless Integration of Detection and Therapy for Breast Cancer Using Targeted Engineered Nanoparticles. Fort Belvoir, VA: Defense Technical Information Center, June 2005. http://dx.doi.org/10.21236/ada446343.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Band, Hamid, Srikumar Raja, and Tatiana Bronich. Mechanism-Based Enhanced Delivery of Drug-Loaded Targeted Nanoparticles for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, February 2013. http://dx.doi.org/10.21236/ada577110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bronich, Tatiana, Hamid Band, and Srikumar Raja. Mechanism-Based Enhanced Delivery of Drug-Loaded Targeted Nanoparticles for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, February 2013. http://dx.doi.org/10.21236/ada580965.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Band, Hamid, and Tatiana Bronich. Mechanism-Based Enhanced Delivery of Drug-Loaded Targeted Nanoparticles for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, February 2014. http://dx.doi.org/10.21236/ada599969.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Nanoparticles, Breast Cancer, BOS' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography